Effects of Ricinoleic Acid (Castor Oil) on Gut Permeability in Healthy Participants: Provocative Test for Treatments Aimed at Restoring Barrier Function.

IF 3 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Clinical and Translational Gastroenterology Pub Date : 2025-05-28 DOI:10.14309/ctg.0000000000000865

David Yi Yang, Camille Lupianez-Merly, Kara Jencks, Saam Dilmaghani, Irene Busciglio, Deborah Eckert, Michael Ryks, Roy Dyer, Brady A Vizenor, Yuxi Zhao, Anna Sapone, Michelle G Rooks, Jeremy D Gale, Michael Camilleri

{"title":"Effects of Ricinoleic Acid (Castor Oil) on Gut Permeability in Healthy Participants: Provocative Test for Treatments Aimed at Restoring Barrier Function.","authors":"David Yi Yang, Camille Lupianez-Merly, Kara Jencks, Saam Dilmaghani, Irene Busciglio, Deborah Eckert, Michael Ryks, Roy Dyer, Brady A Vizenor, Yuxi Zhao, Anna Sapone, Michelle G Rooks, Jeremy D Gale, Michael Camilleri","doi":"10.14309/ctg.0000000000000865","DOIUrl":null,"url":null,"abstract":"Introduction: Altered intestinal permeability (IP) is implicated in multiple gastrointestinal and systemic disease conditions; an experimental model of perturbed IP in healthy subjects is needed. Traditional approaches to perturbing IP include use of nonsteroidal anti-inflammatory drugs (NSAIDs).Methods: We conducted a single-center, randomized, placebo-controlled pilot study of dose-related effects of CO (and its ingredient ricinoleic acid [RA]) at 750, 1500, or 3000 mg daily doses on IP. Permeability was assessed using validated 13C-mannitol and lactulose urine excretion at 0-2h, 8-24h, 0-24h after oral administration.Results: Permeability analysis across all groups demonstrated significant difference among the groups for 0-2h 13C-mannitol, 0-24h 13C-mannitol, and borderline significant difference for 2-8h 13C-mannitol (p=0.060) and 0-24h lactulose (p=0.056). Direct comparison of 3000 mg CO vs. placebo (t-test) demonstrated higher excretion of 13C-mannitol and lactulose at 0-2h, and 0-24h, and lactulose at 2-8h.Conclusion: CO may perturb small intestinal and colonic permeability in healthy adults.","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000865","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Altered intestinal permeability (IP) is implicated in multiple gastrointestinal and systemic disease conditions; an experimental model of perturbed IP in healthy subjects is needed. Traditional approaches to perturbing IP include use of nonsteroidal anti-inflammatory drugs (NSAIDs).

Methods: We conducted a single-center, randomized, placebo-controlled pilot study of dose-related effects of CO (and its ingredient ricinoleic acid [RA]) at 750, 1500, or 3000 mg daily doses on IP. Permeability was assessed using validated 13C-mannitol and lactulose urine excretion at 0-2h, 8-24h, 0-24h after oral administration.

Results: Permeability analysis across all groups demonstrated significant difference among the groups for 0-2h 13C-mannitol, 0-24h 13C-mannitol, and borderline significant difference for 2-8h 13C-mannitol (p=0.060) and 0-24h lactulose (p=0.056). Direct comparison of 3000 mg CO vs. placebo (t-test) demonstrated higher excretion of 13C-mannitol and lactulose at 0-2h, and 0-24h, and lactulose at 2-8h.

Conclusion: CO may perturb small intestinal and colonic permeability in healthy adults.

查看原文本刊更多论文

蓖麻油酸（蓖麻油）对健康参与者肠道通透性的影响：旨在恢复屏障功能治疗的挑衅性试验。

肠通透性改变（IP）与多种胃肠道和全身性疾病有关；需要在健康受试者中建立受扰动IP的实验模型。干扰IP的传统方法包括使用非甾体抗炎药（NSAIDs）。方法：我们进行了一项单中心、随机、安慰剂对照的初步研究，研究CO（及其成分蓖麻油酸[RA]）每日剂量为750、1500或3000 mg对IP的剂量相关影响。通过口服给药后0-2h、8-24h、0-24h验证的13c -甘露醇和乳果糖尿排泄来评估渗透性。结果：各组渗透性分析显示，0-2h 13c -甘露醇、0-24h 13c -甘露醇组间存在显著性差异，2-8h 13c -甘露醇和0-24h乳果糖组间存在显著性差异（p=0.060）。直接比较3000 mg CO与安慰剂（t检验）表明，在0-2h、0-24h和2-8h时，13c -甘露醇和乳果糖的排泄量更高。结论：一氧化碳可扰乱健康成人小肠和结肠的通透性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

7.00

自引率

0.00%

发文量

114

审稿时长

16 weeks

期刊介绍： Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease. Colon and small bowel Endoscopy and novel diagnostics Esophagus Functional GI disorders Immunology of the GI tract Microbiology of the GI tract Inflammatory bowel disease Pancreas and biliary tract Liver Pathology Pediatrics Preventative medicine Nutrition/obesity Stomach.